WHO Unveils GLP-1 Guidelines

Scientific AmericanMonday, December 1, 2025 at 1:45:00 PM
PositiveScience
  • The World Health Organization (WHO) has introduced new guidelines advocating for a global obesity treatment ecosystem to ensure equitable access to GLP-1 weight-loss medications. This initiative aims to address the rising obesity epidemic and promote fair usage of these drugs worldwide.
  • The WHO's guidance is significant as it seeks to standardize the use of GLP-1 medications, which have gained popularity for their effectiveness in weight management. By establishing a framework, the WHO aims to enhance treatment accessibility and address disparities in healthcare.
  • This development occurs amidst ongoing discussions regarding the safety and efficacy of GLP-1 drugs, particularly in light of recent studies highlighting potential risks associated with their use, such as adverse pregnancy outcomes and lack of cognitive benefits in certain populations. These contrasting findings underscore the complexity of obesity treatment and the need for comprehensive research and guidelines.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended apps based on your readingExplore all apps
Continue Readings
Wegovy Pill Becomes First Oral GLP-1 Weight-Loss Drug Approved in U.S.
PositiveScience
The U.S. has approved an oral version of Wegovy, the first GLP-1 weight-loss drug available in pill form, marking a significant advancement in obesity treatment options. This approval is expected to enhance accessibility for patients seeking effective weight management solutions.

Ready to build your own newsroom?

Subscribe to unlock a personalised feed, podcasts, newsletters, and notifications tailored to the topics you actually care about